These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 15573900)
41. Levofloxacin in the treatment of community-acquired pneumonia. Noreddin AM; Elkhatib WF Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. Tasso L; de Andrade C; Dalla Costa T Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621 [TBL] [Abstract][Full Text] [Related]
45. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections. Kawai T Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383 [No Abstract] [Full Text] [Related]
46. Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin. Pallecchi L; Riccobono E; Montagnani F; Di Maggio T; Mantengoli E; Pollini S; Rossolini GM J Chemother; 2011 Oct; 23(5):308-9. PubMed ID: 22005066 [No Abstract] [Full Text] [Related]
47. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298 [TBL] [Abstract][Full Text] [Related]
48. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Bhavnani SM; Hammel JP; Jones RN; Ambrose PG Diagn Microbiol Infect Dis; 2005 Jan; 51(1):31-7. PubMed ID: 15629226 [TBL] [Abstract][Full Text] [Related]
49. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill. Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951 [TBL] [Abstract][Full Text] [Related]
50. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. von Gottberg A; Klugman KP; Cohen C; Wolter N; de Gouveia L; du Plessis M; Mpembe R; Quan V; Whitelaw A; Hoffmann R; Govender N; Meiring S; Smith AM; Schrag S; Lancet; 2008 Mar; 371(9618):1108-13. PubMed ID: 18359074 [TBL] [Abstract][Full Text] [Related]
51. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924 [TBL] [Abstract][Full Text] [Related]
52. Activity of levofloxacin, ofloxacin, D-ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals. Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Seibert G; Iyer P Drugs; 1995; 49 Suppl 2():211-4. PubMed ID: 8549307 [No Abstract] [Full Text] [Related]
53. Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. Rubinstein E J Antimicrob Chemother; 2003 May; 51(5):1307-8; author reply 1308-9. PubMed ID: 12697636 [No Abstract] [Full Text] [Related]
54. Antimicrobial screening of Nicotiana tobacum on organisms isolated from patients with respiratory tract infection. Adeleye IA; Uwagboe UC West Indian Med J; 2003 Dec; 52(4):325-6. PubMed ID: 15040073 [No Abstract] [Full Text] [Related]